{"transactions":[{"id":1508734,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":90816,"kind":"person","name":"CONWAY ROBERT E","position":1,"cik":"0001184334","reported_name":"CONWAY ROBERT E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-20T20:11:51.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"(Continued from Footnote 5) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"1/12th of the shares subject to the option become vested and exercisable on February 2, 2024 and 1/12 of the shares subject to the option shall vest monthly thereafter."}],"balance_after":0,"derivative":{"exercise_price":19,"expiration_date":"2034-01-01","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001626199-24-000098","document":"wk-form4_1716250302.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1184334/000162619924000098/wk-form4_1716250302.xml","form_type":"4"}},{"id":1508733,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":90816,"kind":"person","name":"CONWAY ROBERT E","position":1,"cik":"0001184334","reported_name":"CONWAY ROBERT E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-20T20:11:51.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"(Continued from Footnote 5) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":7.43,"expiration_date":"2033-01-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001626199-24-000098","document":"wk-form4_1716250302.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1184334/000162619924000098/wk-form4_1716250302.xml","form_type":"4"}},{"id":1508732,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":90816,"kind":"person","name":"CONWAY ROBERT E","position":1,"cik":"0001184334","reported_name":"CONWAY ROBERT E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-20T20:11:51.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"(Continued from Footnote 5) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":13.89,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001626199-24-000098","document":"wk-form4_1716250302.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1184334/000162619924000098/wk-form4_1716250302.xml","form_type":"4"}},{"id":1508731,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":90816,"kind":"person","name":"CONWAY ROBERT E","position":1,"cik":"0001184334","reported_name":"CONWAY ROBERT E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-20T20:11:51.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7650,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"(Continued from Footnote 5) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":13.45,"expiration_date":"2031-01-03","underlying":"Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0001626199-24-000098","document":"wk-form4_1716250302.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1184334/000162619924000098/wk-form4_1716250302.xml","form_type":"4"}},{"id":1508730,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":90816,"kind":"person","name":"CONWAY ROBERT E","position":1,"cik":"0001184334","reported_name":"CONWAY ROBERT E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-20T20:11:51.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7650,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"(Continued from Footnote 5) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":3.6233,"expiration_date":"2030-01-01","underlying":"Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0001626199-24-000098","document":"wk-form4_1716250302.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1184334/000162619924000098/wk-form4_1716250302.xml","form_type":"4"}},{"id":1508729,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":90816,"kind":"person","name":"CONWAY ROBERT E","position":1,"cik":"0001184334","reported_name":"CONWAY ROBERT E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-20T20:11:51.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7650,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"(Continued from Footnote 5) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":4.09,"expiration_date":"2029-01-01","underlying":"Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0001626199-24-000098","document":"wk-form4_1716250302.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1184334/000162619924000098/wk-form4_1716250302.xml","form_type":"4"}},{"id":1508728,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":90816,"kind":"person","name":"CONWAY ROBERT E","position":1,"cik":"0001184334","reported_name":"CONWAY ROBERT E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-20T20:11:51.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7650,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"(Continued from Footnote 5) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":11.31,"expiration_date":"2028-01-01","underlying":"Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0001626199-24-000098","document":"wk-form4_1716250302.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1184334/000162619924000098/wk-form4_1716250302.xml","form_type":"4"}},{"id":1508727,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":90816,"kind":"person","name":"CONWAY ROBERT E","position":1,"cik":"0001184334","reported_name":"CONWAY ROBERT E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-20T20:11:51.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1912,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"(Continued from Footnote 5) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":61.12,"expiration_date":"2025-09-11","underlying":"Common Stock","underlying_shares":1912},"source":{"system":"sec-edgar","filing":"0001626199-24-000098","document":"wk-form4_1716250302.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1184334/000162619924000098/wk-form4_1716250302.xml","form_type":"4"}},{"id":1508726,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":90816,"kind":"person","name":"CONWAY ROBERT E","position":1,"cik":"0001184334","reported_name":"CONWAY ROBERT E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-20T20:11:51.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3075,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"(Continued from Footnote 5) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":31.08,"expiration_date":"2026-09-12","underlying":"Common Stock","underlying_shares":3075},"source":{"system":"sec-edgar","filing":"0001626199-24-000098","document":"wk-form4_1716250302.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1184334/000162619924000098/wk-form4_1716250302.xml","form_type":"4"}},{"id":1508725,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":90816,"kind":"person","name":"CONWAY ROBERT E","position":1,"cik":"0001184334","reported_name":"CONWAY ROBERT E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-20T20:11:51.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2868,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"(Continued from Footnote 5) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":69.96,"expiration_date":"2025-07-16","underlying":"Common Stock","underlying_shares":2868},"source":{"system":"sec-edgar","filing":"0001626199-24-000098","document":"wk-form4_1716250302.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1184334/000162619924000098/wk-form4_1716250302.xml","form_type":"4"}},{"id":1508724,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":90816,"kind":"person","name":"CONWAY ROBERT E","position":1,"cik":"0001184334","reported_name":"CONWAY ROBERT E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-20T20:11:51.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":50000,"ownership":{"direct":false,"nature":"By Robert E. Conway Rev Trust and Carolyn J. Conway Rev Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001626199-24-000098","document":"wk-form4_1716250302.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184334/000162619924000098/wk-form4_1716250302.xml","form_type":"4"}},{"id":1665742,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":90816,"kind":"person","name":"CONWAY ROBERT E","position":1,"cik":"0001184334","reported_name":"CONWAY ROBERT E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Chairman of the Board"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-31T21:25:24.000Z","date":"2024-01-30","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan, vesting in 12 equal monthly installments beginning as of January 30, 2024, subject to the Reporting Person continuing to provide Continuous Service (as defined in the 2020 Equity Incentive Plan) through such date. If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested."}],"balance_after":6000,"derivative":{"exercise_price":1.64,"expiration_date":"2034-01-30","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-24-002478","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/907654/000120919124002478/doc4.xml","form_type":"4"}},{"id":1687297,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":90816,"kind":"person","name":"CONWAY ROBERT E","position":1,"cik":"0001184334","reported_name":"CONWAY ROBERT E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-01-04T19:07:45.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/12th of the shares subject to the option become vested and exercisable on February 2, 2024 and 1/12 of the shares subject to the option shall vest monthly thereafter."}],"balance_after":17500,"derivative":{"exercise_price":19,"expiration_date":"2034-01-01","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001626199-24-000014","document":"wk-form4_1704413242.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184334/000162619924000014/wk-form4_1704413242.xml","form_type":"4"}},{"id":2062056,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":90816,"kind":"person","name":"CONWAY ROBERT E","position":1,"cik":"0001184334","reported_name":"CONWAY ROBERT E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2023-01-05T18:56:22.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/12th of the shares subject to the option become vested and exercisable on February 3, 2023 and 1/12 of the shares subject to the option shall vest monthly thereafter."}],"balance_after":10000,"derivative":{"exercise_price":7.43,"expiration_date":"2033-01-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001626199-23-000016","document":"wf-form4_167296296563582.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184334/000162619923000016/wf-form4_167296296563582.xml","form_type":"4"}},{"id":2082554,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":90816,"kind":"person","name":"CONWAY ROBERT E","position":1,"cik":"0001184334","reported_name":"CONWAY ROBERT E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Chairman of the Board"}}],"security":"Stock Option (right to buy)","published_at":"2022-12-19T21:20:06.000Z","date":"2022-12-15","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan, vesting in 12 equal monthly installments beginning as of December 15, 2022.  If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested."}],"balance_after":6000,"derivative":{"exercise_price":2.32,"expiration_date":"2032-12-15","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-22-061901","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/907654/000120919122061901/doc4.xml","form_type":"4"}},{"id":2448077,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":90816,"kind":"person","name":"CONWAY ROBERT E","position":1,"cik":"0001184334","reported_name":"CONWAY ROBERT E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2022-01-04T17:31:43.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/12th of the shares subject to the option become vested and exercisable on February 3, 2022 and 1/12th of the shares subject to the option shall vest monthly thereafter."}],"balance_after":10000,"derivative":{"exercise_price":13.89,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001626199-22-000012","document":"wf-form4_164133547773725.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184334/000162619922000012/wf-form4_164133547773725.xml","form_type":"4"}},{"id":2558700,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":90816,"kind":"person","name":"CONWAY ROBERT E","position":1,"cik":"0001184334","reported_name":"CONWAY ROBERT E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-27T07:02:20.000Z","date":"2021-09-23","kind":"purchase","acquired":true,"shares":15000,"price":10.0769,"value":151153.5,"ownership":{"direct":false,"nature":"By Robert E. Conway Rev Trust and Carolyn J. Conway Rev Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Form 4 filed on September 24, 2021 inadvertently included an incorrect transaction code for the reported transaction. The transaction code included on the original Form 4 was \"S\" while the correct transaction code should have been \"P\"."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $9.945 to $10.20.  The price reported above reflects the weighted average purchase price.  The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001626199-21-000130","document":"wf-form4a_163274052780471.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184334/000162619921000130/wf-form4a_163274052780471.xml","form_type":"4/A","original_submission_date":"2021-09-24"}},{"id":2559723,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":90816,"kind":"person","name":"CONWAY ROBERT E","position":1,"cik":"0001184334","reported_name":"CONWAY ROBERT E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-24T18:39:05.000Z","date":"2021-09-23","kind":"sale","acquired":true,"shares":15000,"price":10.0769,"value":151153.5,"ownership":{"direct":false,"nature":"By Robert E. Conway Rev Trust and Carolyn J. Conway Rev Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"(1)This transaction was executed in multiple trades at prices ranging from $9.945 to $10.20.  The price reported above reflects the weighted average sale price.  The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001626199-21-000127","document":"wf-form4_163252313299208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184334/000162619921000127/wf-form4_163252313299208.xml","form_type":"4"}},{"id":2560748,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":90816,"kind":"person","name":"CONWAY ROBERT E","position":1,"cik":"0001184334","reported_name":"CONWAY ROBERT E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-23T20:31:02.000Z","date":"2021-09-21","kind":"purchase","acquired":true,"shares":10000,"price":9.7966,"value":97966.0,"ownership":{"direct":false,"nature":"By Robert E. Conway Rev Trust and Carolyn J. Conway Rev Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $9.75 to $9.8299. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":35000,"source":{"system":"sec-edgar","filing":"0001626199-21-000120","document":"wf-form4_163244344151145.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184334/000162619921000120/wf-form4_163244344151145.xml","form_type":"4"}},{"id":2715245,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":90816,"kind":"person","name":"CONWAY ROBERT E","position":1,"cik":"0001184334","reported_name":"CONWAY ROBERT E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Chairman of the Board"}}],"security":"Common Stock","published_at":"2021-05-13T21:00:43.000Z","date":"2021-05-12","kind":"purchase","acquired":true,"shares":10000,"price":3.1947,"value":31947.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from\n$3.18 to $3.20. Upon request of the SEC staff, ARCA biopharma, Inc. (the \"Company\") or a security holder of the Company, the reporting person\nwill provide full information regarding the number of shares purchased at each separate price."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001209191-21-032381","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/907654/000120919121032381/doc4.xml","form_type":"4"}},{"id":2725562,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":90816,"kind":"person","name":"CONWAY ROBERT E","position":1,"cik":"0001184334","reported_name":"CONWAY ROBERT E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Chairman of the Board"}}],"security":"Common Stock","published_at":"2021-05-06T20:30:31.000Z","date":"2021-05-05","kind":"purchase","acquired":true,"shares":10000,"price":3.2345,"value":32345.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from\n$3.229 to $3.24. Upon request of the SEC staff, ARCA biopharma, Inc. (the \"Company\") or a security holder of the Company, the reporting person\nwill provide full information regarding the number of shares purchased at each separate price."}],"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001209191-21-030629","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/907654/000120919121030629/doc4.xml","form_type":"4"}},{"id":2908764,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":90816,"kind":"person","name":"CONWAY ROBERT E","position":1,"cik":"0001184334","reported_name":"CONWAY ROBERT E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Chairman of the Board"}}],"security":"Stock Option (right to buy)","published_at":"2021-01-14T00:04:38.000Z","date":"2021-01-12","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan, vesting in 36 equal monthly installments beginning as of December 21, 2020.  If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested."}],"balance_after":12000,"derivative":{"exercise_price":4.31,"expiration_date":"2031-01-12","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-21-003468","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/907654/000120919121003468/doc4.xml","form_type":"4"}},{"id":2919754,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":90816,"kind":"person","name":"CONWAY ROBERT E","position":1,"cik":"0001184334","reported_name":"CONWAY ROBERT E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2021-01-05T19:02:18.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":7650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/12th of the shares subject to the option become vested and exercisable on February 4, 2021 and 1/12th of the shares subject to the option shall vest monthly thereafter."}],"balance_after":7650,"derivative":{"exercise_price":13.45,"expiration_date":"2031-01-03","underlying":"Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0001626199-21-000018","document":"wf-form4_160989132098382.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184334/000162619921000018/wf-form4_160989132098382.xml","form_type":"4"}},{"id":2936767,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":90816,"kind":"person","name":"CONWAY ROBERT E","position":1,"cik":"0001184334","reported_name":"CONWAY ROBERT E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Chairman of the Board"}}],"security":"Common Stock","published_at":"2020-12-21T21:15:11.000Z","date":"2020-12-18","kind":"purchase","acquired":true,"shares":10000,"price":4.163,"value":41630.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from\n$4.1497 to $4.1696. Upon request of the SEC staff, ARCA biopharma, Inc. (the \"Company\") or a security holder of the Company, the reporting person\nwill provide full information regarding the number of shares purchased at each separate price."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001209191-20-064624","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/907654/000120919120064624/doc4.xml","form_type":"4"}},{"id":2969669,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":90816,"kind":"person","name":"CONWAY ROBERT E","position":1,"cik":"0001184334","reported_name":"CONWAY ROBERT E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-23T17:00:09.000Z","date":"2020-11-19","kind":"purchase","acquired":true,"shares":10000,"price":8.03,"value":80300.0,"ownership":{"direct":false,"nature":"By Robert E. Conway Rev Trust and Carolyn J. Conway Rev Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $7.88 to $8.0999.  The price reported above reflects the weighted average purchase price.  The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0000899243-20-031924","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184334/000089924320031924/doc4.xml","form_type":"4"}},{"id":3022595,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":90816,"kind":"person","name":"CONWAY ROBERT E","position":1,"cik":"0001184334","reported_name":"CONWAY ROBERT E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Chairman of the Board"}}],"security":"Common Stock","published_at":"2020-09-25T20:20:09.000Z","date":"2020-09-25","kind":"purchase","acquired":true,"shares":5000,"price":4.2799,"value":21399.5,"ownership":{"direct":true},"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001209191-20-052094","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/907654/000120919120052094/doc4.xml","form_type":"4"}},{"id":3023225,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":90816,"kind":"person","name":"CONWAY ROBERT E","position":1,"cik":"0001184334","reported_name":"CONWAY ROBERT E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Chairman of the Board"}}],"security":"Common Stock","published_at":"2020-09-24T20:20:12.000Z","date":"2020-09-22","kind":"purchase","acquired":true,"shares":3056,"price":4.6599,"value":14240.6544,"ownership":{"direct":true},"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001209191-20-051890","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/907654/000120919120051890/doc4.xml","form_type":"4"}},{"id":3026364,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":90816,"kind":"person","name":"CONWAY ROBERT E","position":1,"cik":"0001184334","reported_name":"CONWAY ROBERT E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Chairman of the Board"}}],"security":"Common Stock","published_at":"2020-09-21T21:00:11.000Z","date":"2020-09-21","kind":"purchase","acquired":true,"shares":10000,"price":4.766,"value":47660.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price represents the weighted average sale price for multiple transactions reported on this line.  The prices of the transactions ranged from $4.743 to $4.80.  Upon request of the SEC staff, ARCA biopharma, Inc. (the \"Company\") or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":11944,"source":{"system":"sec-edgar","filing":"0001209191-20-051302","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/907654/000120919120051302/doc4.xml","form_type":"4"}},{"id":3317912,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":90816,"kind":"person","name":"CONWAY ROBERT E","position":1,"cik":"0001184334","reported_name":"CONWAY ROBERT E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2020-01-06T20:01:59.000Z","date":"2020-01-02","kind":"grant","acquired":true,"shares":7650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/12th of the shares subject to the option become vested and exercisable on February 2, 2020 and 1/12th of the shares subject to the option shall vest monthly thereafter."}],"balance_after":7650,"derivative":{"exercise_price":3.6233,"expiration_date":"2030-01-01","underlying":"Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0000899243-20-000640","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184334/000089924320000640/doc4.xml","form_type":"4"}},{"id":3703463,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":90816,"kind":"person","name":"CONWAY ROBERT E","position":1,"cik":"0001184334","reported_name":"CONWAY ROBERT E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2019-01-04T16:02:07.000Z","date":"2019-01-02","kind":"grant","acquired":true,"shares":7650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/12th of the shares subject to the option become vested and exercisable on February 2, 2019 and 1/12th of the shares subject to the option shall vest monthly thereafter."}],"balance_after":7650,"derivative":{"exercise_price":4.09,"expiration_date":"2029-01-01","underlying":"Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0000899243-19-000500","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184334/000089924319000500/doc4.xml","form_type":"4"}},{"id":4017302,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":90816,"kind":"person","name":"CONWAY ROBERT E","position":1,"cik":"0001184334","reported_name":"CONWAY ROBERT E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Chairman of the Board"}}],"security":"Stock Option (right to buy)","published_at":"2018-03-05T22:35:18.000Z","date":"2018-03-01","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Grant to the Reporting Person of a stock option under the 2013 Amended and Restated Equity Incentive Plan, vesting in 12 equal monthly installments beginning as of January 1, 2018.  If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested."}],"balance_after":8000,"derivative":{"exercise_price":0.72,"expiration_date":"2028-02-29","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001209191-18-016698","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/907654/000120919118016698/doc4.xml","form_type":"4"}},{"id":4107081,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":90816,"kind":"person","name":"CONWAY ROBERT E","position":1,"cik":"0001184334","reported_name":"CONWAY ROBERT E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2018-01-04T17:18:52.000Z","date":"2018-01-02","kind":"grant","acquired":true,"shares":7650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the shares subject to the option become vested and exercisable on January 2, 2019."}],"balance_after":7650,"derivative":{"exercise_price":11.31,"expiration_date":"2028-01-01","underlying":"Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0000899243-18-000492","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184334/000089924318000492/doc4.xml","form_type":"4"}},{"id":4256624,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":90816,"kind":"person","name":"CONWAY ROBERT E","position":1,"cik":"0001184334","reported_name":"CONWAY ROBERT E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Chairman of the Board"}}],"security":"Common Stock","published_at":"2017-07-17T20:08:30.000Z","date":"2017-07-14","kind":"purchase","acquired":true,"shares":10000,"price":2.49,"value":24900.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions ranged from\n$2.475 to $2.55. Upon request of the SEC staff, ARCA biopharma, Inc. (the \"Company\") or a security holder of the Company, the reporting person\nwill provide full information regarding the number of shares sold at each separate price."}],"balance_after":35000,"source":{"system":"sec-edgar","filing":"0001209191-17-045336","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/907654/000120919117045336/doc4.xml","form_type":"4"}},{"id":4324454,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":90816,"kind":"person","name":"CONWAY ROBERT E","position":1,"cik":"0001184334","reported_name":"CONWAY ROBERT E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-05-11T12:17:27.000Z","date":"2017-05-08","kind":"purchase","acquired":true,"shares":15000,"price":2.28,"value":34200.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price recorded in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.244 to $2.329, inclusive. The reporting person undertakes to provide Nivalis Therapeutics, Inc., any security holder of Nivalis Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4."}],"balance_after":60000,"source":{"system":"sec-edgar","filing":"0001104659-17-031830","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184334/000110465917031830/a4.xml","form_type":"4"}},{"id":4326442,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":90816,"kind":"person","name":"CONWAY ROBERT E","position":1,"cik":"0001184334","reported_name":"CONWAY ROBERT E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-05-10T14:00:27.000Z","date":"2017-05-09","kind":"purchase","acquired":true,"shares":5000,"price":2.34,"value":11700.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price recorded in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.313 to $2.349, inclusive. The reporting person undertakes to provide Nivalis Therapeutics, Inc., any security holder of Nivalis Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4."}],"balance_after":45000,"source":{"system":"sec-edgar","filing":"0001104659-17-031472","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184334/000110465917031472/a4.xml","form_type":"4"}},{"id":4328076,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":90816,"kind":"person","name":"CONWAY ROBERT E","position":1,"cik":"0001184334","reported_name":"CONWAY ROBERT E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-05-09T14:01:11.000Z","date":"2017-05-05","kind":"purchase","acquired":true,"shares":20000,"price":2.3,"value":46000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price recorded in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.262 to $2.338, inclusive. The reporting person undertakes to provide Nivalis Therapeutics, Inc., any security holder of Nivalis Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4."}],"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001104659-17-031085","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184334/000110465917031085/a4.xml","form_type":"4"}},{"id":4329860,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":90816,"kind":"person","name":"CONWAY ROBERT E","position":1,"cik":"0001184334","reported_name":"CONWAY ROBERT E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-05-08T14:00:41.000Z","date":"2017-05-04","kind":"purchase","acquired":true,"shares":10000,"price":2.26,"value":22600.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price recorded in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.247 to $2.288, inclusive. The reporting person undertakes to provide Nivalis Therapeutics, Inc., any security holder of Nivalis Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4."}],"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001104659-17-030597","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184334/000110465917030597/a4.xml","form_type":"4"}},{"id":4371939,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":90816,"kind":"person","name":"CONWAY ROBERT E","position":1,"cik":"0001184334","reported_name":"CONWAY ROBERT E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-03-27T20:06:24.000Z","date":"2017-03-24","kind":"purchase","acquired":true,"shares":25000,"price":2.59,"value":64750.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions ranged from\n$2.52 to $2.75. Upon request of the SEC staff, ARCA biopharma, Inc. (the \"Company\") or a security holder of the Company, the reporting person\nwill provide full information regarding the number of shares sold at each separate price"}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001209191-17-022934","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/907654/000120919117022934/doc4.xml","form_type":"4"}},{"id":4437399,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":90816,"kind":"person","name":"CONWAY ROBERT E","position":1,"cik":"0001184334","reported_name":"CONWAY ROBERT E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-02-21T21:49:56.000Z","date":"2017-02-16","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Grant to the Reporting Person of a stock option under the 2013 Amended and Restated Equity Incentive Plan, vesting in 12 equal monthly installments beginning as of January 1, 2017.  If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested."}],"balance_after":8000,"derivative":{"exercise_price":2.5,"expiration_date":"2027-02-15","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001209191-17-012758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/907654/000120919117012758/doc4.xml","form_type":"4"}},{"id":4603143,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":90816,"kind":"person","name":"CONWAY ROBERT E","position":1,"cik":"0001184334","reported_name":"CONWAY ROBERT E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2016-09-14T16:16:03.000Z","date":"2016-09-12","kind":"grant","acquired":true,"shares":12300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares shall vest in 12 equal monthly installments commencing on October 12, 2016."}],"balance_after":12300,"derivative":{"exercise_price":7.77,"expiration_date":"2026-09-12","underlying":"Common Stock","underlying_shares":12300},"source":{"system":"sec-edgar","filing":"0001104659-16-144631","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184334/000110465916144631/a4.xml","form_type":"4"}}]}